Livagen is a lab made peptide built from four amino acids, developed by a research team in St Petersburg, Russia, led by Vladimir Khavinson, as a synthetic version of a natural substance drawn from liver tissue. Roughly fifteen papers indexed in a major medical database cover it, mostly from a closely linked research network, and the record consists almost entirely of laboratory cell work and short animal studies rather than trials in people.
What it is
Livagen has a verified four amino acid sequence, lysine, glutamate, aspartate and alanine, written in short form as KEDA. It belongs to a class of short peptides researchers call bioregulators, a term used for small peptides studied for their proposed effect on gene activity rather than for blocking or activating a single well defined receptor.
Nearly all of the published research on Livagen comes from the same St Petersburg research group and its collaborators rather than from a broad, independent scientific community. No randomized controlled trial, no measured human pharmacokinetic study describing how it moves through the body, and no fully independent replication outside the original network has been published in the record reviewed for this entry.
How it is studied
Research on Livagen comes from white blood cells taken from elderly human donors and studied outside the body, laboratory enzyme tests using human serum, and short feeding studies in rats. No study giving Livagen to a living human participant and measuring an outcome was identified for this entry.
What studies report
- A study using white blood cells taken from elderly donors and studied outside the body reported that Livagen loosened tightly packed sections of DNA called heterochromatin and reactivated ribosomal genes that are normally switched off with age. [1]
- A laboratory enzyme study using human blood serum reported that Livagen blocked an enzyme that breaks down the body's own natural pain modulating chemicals called enkephalins, working better in this narrow test than three older comparison substances, while not directly attaching to the opioid receptors those chemicals use. [2]
- A two week feeding study in rats reported that Livagen was barely broken down by digestive enzymes in the small intestine, and that a digestive enzyme's activity dropped in young rats given the peptide but rose in old rats, moving closer to the level seen in untreated young rats. [3]
What is not known
No human trial and no measured human pharmacokinetic profile for Livagen has been published, and no research group outside the original Khavinson linked network has independently repeated these findings. It is not known whether the cell based chromatin findings or the rat feeding results would apply to a living person, and mentions of effects in conditions such as liver disease come from review articles rather than original research.
Regulatory status
Livagen has no approval from the United States Food and Drug Administration, the European Medicines Agency, or a verified Russian pharmaceutical registration. It is distributed internationally as a research chemical, with its most complete evidence sitting in cell and animal studies rather than any approved human use.
Research reporting only. Nothing on this site is medical advice, a diagnosis, or a recommendation to take, stop or change any medicine.
Sources
- Effects of Livagen peptide on chromatin activation in lymphocytes from old peopleBulletin of Experimental Biology and Medicine, 2002
- Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serumIzvestiia Akademii Nauk. Seriia Biologicheskaia, 2003
- Effect of the peptide Livagen on the activity of digestive enzymes in the gastrointestinal tract and non-digestive organs in rats of different agesAdvances in Gerontology, 2005
Last reviewed 7 September 2026